Clinical Trials Logo

Filter by:
NCT ID: NCT02940353 Completed - Clinical trials for Edentulous or Failing Dentition Mandible

The TREFOIL Concept 5 Year Clinical Investigation

Start date: April 2016
Phase: N/A
Study type: Interventional

Prospective, single cohort, multi-center study evaluating the TREFOIL concept for the treatment of edentulous or patients with failing mandibular dentition over 5 years. 90 patients (15 per centre) will be included. The subject population is at least 18 years old, in need of an implant restored full prosthesis providing sufficient bone in the interforaminal where a fixed restoration on three implants is regarded as an appropriate treatment solution. The components are TREFOIL treatment concept (implants and framework).

NCT ID: NCT02939989 Completed - Clinical trials for Hepatitis C Virus Infection

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

MAGELLAN-3
Start date: November 21, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic with compensated cirrhosis participants) who had experienced virologic failure in an AbbVie parent clinical study.

NCT ID: NCT02939586 Completed - Sleep Clinical Trials

The Effect of Haemodialysis in Sleep Apnoea

Start date: October 2016
Phase: N/A
Study type: Interventional

Sleep disturbance is a significant issue in people undergoing dialysis. More than 80% of haemodialysis patients complain of difficulty sleeping. Inadequate sleep can cause poor daytime function and increased risk of motor vehicle incidents. One of the common reasons for sleep disturbance in dialysis patients is sleep apnoea. Sleep apnoea involves pauses in breathing that occur during sleep. Each pause can last only a few seconds or minutes. Severe sleep apnoea reduces oxygen supply and increases risk of heart attack and stroke, which are the leading causes of death in dialysis patients. In this project, the investigators will examine how a change of dialysis treatment might improve sleep. This project will first identify patients at risk of sleep disturbance using surveys and a subsequent sleep study. The investigators will then test different dialysis models to see the effect of dialysis treatment on sleep apnoea. The aim is to find a dialysis model that works better for patients with sleep apnoea.

NCT ID: NCT02939183 Completed - Clinical trials for Relapsed or Refractory Multiple Myeloma

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

INTREPID-1
Start date: January 17, 2017
Phase: Phase 1
Study type: Interventional

A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma.

NCT ID: NCT02937701 Completed - Clinical trials for Arthritis, Rheumatoid

Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

Start date: October 10, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of the study was to compare rheumatoid arthritis symptom improvement in participants who were given ABP 710 to those who were given infliximab, 22 weeks after starting treatment.

NCT ID: NCT02935634 Completed - Clinical trials for Advanced Gastric Cancer

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

FRACTION-GC
Start date: November 29, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

NCT ID: NCT02934412 Completed - Psoriasis Clinical Trials

A Study of SHR-1314 in Healthy Subjects

Start date: August 22, 2016
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single dose escalating, study in 5 sequential cohorts to investigate the effect of a single s.c. injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects. Each cohort will consist of 6 subjects receiving active drug and 2 subjects receiving placebo, for a total of approximately 40 subjects dosed at one study site.

NCT ID: NCT02933606 Completed - Clinical trials for Post-Traumatic Stress Disorder

Phase II Study of BNC210 in PTSD

RESTORE
Start date: June 30, 2016
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.

NCT ID: NCT02931838 Completed - Psoriasis Clinical Trials

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Start date: November 15, 2016
Phase: Phase 2
Study type: Interventional

A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165

NCT ID: NCT02931539 Completed - Clinical trials for Cytomegalovirus (CMV)

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Start date: December 22, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.